Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Early Phase 1

2(40.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

N/A

1(20.0%)

5Total

Early Phase 1(2)

Phase 3(1)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00734994Early Phase 1Completed

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Role: lead

NCT00787488Not ApplicableWithdrawn

Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca

Role: lead

NCT00093509Phase 1Completed

MRI Sarcoma Non Invasive Thermometry

Role: lead

NCT00085631Phase 3Terminated

Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer

Role: lead

NCT01055678Early Phase 1Withdrawn

To Evaluate the Characteristics of a Breast Cancer

Role: lead

All 5 trials loaded